Shares of Novavax were buoyed slightly by the news that its mid-stage trial of a closely-watched seasonal flu vaccine demonstrated significant immunogenicity against one of three flu strains among elderly patients with its higher dose. The trial recruited 480 subjects over the age of 60, a key demographic group typically not protected by currently used vaccines. Researchers said there was no statistically significant difference in the seroconversion rate against the other two strains.
"We are pleased to see that both doses of VLP vaccine were well tolerated and immunogenic in older adults, which was a key question for this trial," said CEO Rahul Singhvi. "The finding that a higher dose of VLP vaccine could be more immunogenic in this population is particularly important since there is a significant medical need for a better vaccine for older adults. These data show that our recombinant, VLP-vaccine technology affords great flexibility in using dose as a means to improve the possible effectiveness of the vaccine."
- check out Novavax's release
- read the story from Reuters